Tiziana Life Sciences Ltd stock is down -3.89% since 30 days ago. The next earnings date is Dec 26, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 16.67% of the previous 5 December’s closed higher than November.
Tiziana Life Sciences plc focuses on the discovery and development of molecules to treat human diseases in oncology, inflammation, and infectious diseases. Its lead product candidate in immunology is Foralumab (TZLS-401) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.